Adriaan Van Bokhoven
Concepts (319)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 30 | 2015 | 978 | 1.390 |
Why?
| | Carcinoma | 4 | 2011 | 225 | 0.500 |
Why?
| | Pelvic Pain | 4 | 2026 | 42 | 0.470 |
Why?
| | Prostate | 12 | 2015 | 158 | 0.430 |
Why?
| | Cadherins | 12 | 2007 | 200 | 0.390 |
Why?
| | Cell Line, Tumor | 7 | 2015 | 3542 | 0.310 |
Why?
| | Tumor Cells, Cultured | 11 | 2008 | 886 | 0.260 |
Why?
| | Urinary Bladder Neoplasms | 4 | 2011 | 258 | 0.260 |
Why?
| | Chronic Pain | 2 | 2026 | 291 | 0.250 |
Why?
| | Finasteride | 2 | 2015 | 33 | 0.200 |
Why?
| | Biopsy | 2 | 2015 | 1082 | 0.160 |
Why?
| | Carcinoma, Renal Cell | 4 | 2008 | 230 | 0.160 |
Why?
| | Cell Lineage | 1 | 2001 | 377 | 0.140 |
Why?
| | Cystitis, Interstitial | 2 | 2015 | 20 | 0.140 |
Why?
| | Receptors, Androgen | 2 | 2014 | 148 | 0.140 |
Why?
| | Prostatitis | 2 | 2015 | 17 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2012 | 534 | 0.140 |
Why?
| | Immunohistochemistry | 8 | 2015 | 1716 | 0.130 |
Why?
| | Male | 39 | 2026 | 72843 | 0.120 |
Why?
| | Androstenedione | 1 | 2015 | 10 | 0.110 |
Why?
| | Urinary Tract | 1 | 2015 | 47 | 0.110 |
Why?
| | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 2 | 2008 | 7 | 0.110 |
Why?
| | DNA, Neoplasm | 5 | 2003 | 158 | 0.110 |
Why?
| | Prostatic Hyperplasia | 1 | 2015 | 40 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2011 | 977 | 0.110 |
Why?
| | Proteinuria | 1 | 2014 | 104 | 0.100 |
Why?
| | Trinucleotide Repeats | 1 | 2014 | 31 | 0.100 |
Why?
| | Kidney Neoplasms | 4 | 2008 | 413 | 0.100 |
Why?
| | Adaptive Immunity | 1 | 2015 | 167 | 0.100 |
Why?
| | Karyotyping | 3 | 2003 | 105 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-ets | 1 | 2014 | 56 | 0.100 |
Why?
| | Optics and Photonics | 1 | 2014 | 37 | 0.100 |
Why?
| | Chromosome Aberrations | 3 | 2003 | 166 | 0.100 |
Why?
| | Serine Endopeptidases | 1 | 2014 | 128 | 0.100 |
Why?
| | Biopsy, Needle | 1 | 2014 | 185 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 5 | 2015 | 1443 | 0.100 |
Why?
| | Spectrometry, Fluorescence | 1 | 2014 | 165 | 0.100 |
Why?
| | B7-H1 Antigen | 1 | 2015 | 244 | 0.100 |
Why?
| | Blotting, Western | 5 | 2012 | 1179 | 0.090 |
Why?
| | Androstane-3,17-diol | 1 | 2012 | 2 | 0.090 |
Why?
| | 5-alpha Reductase Inhibitors | 1 | 2012 | 16 | 0.090 |
Why?
| | Glucuronides | 1 | 2012 | 18 | 0.090 |
Why?
| | Biomarkers | 4 | 2026 | 4295 | 0.090 |
Why?
| | Cell Adhesion | 4 | 2004 | 451 | 0.090 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 614 | 0.090 |
Why?
| | Proto-Oncogenes | 1 | 1992 | 28 | 0.090 |
Why?
| | Humans | 49 | 2026 | 145475 | 0.090 |
Why?
| | Cadmium | 1 | 2012 | 68 | 0.090 |
Why?
| | Inflammation | 2 | 2015 | 2878 | 0.090 |
Why?
| | Urothelium | 1 | 2011 | 33 | 0.090 |
Why?
| | Gonadal Steroid Hormones | 1 | 2012 | 143 | 0.080 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2011 | 81 | 0.080 |
Why?
| | Syndrome | 2 | 2026 | 381 | 0.080 |
Why?
| | Cell Division | 3 | 2011 | 756 | 0.080 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2011 | 325 | 0.070 |
Why?
| | Immunity, Innate | 1 | 2015 | 835 | 0.070 |
Why?
| | Epithelial Cells | 4 | 2012 | 1131 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 765 | 0.070 |
Why?
| | Protein-Tyrosine Kinases | 1 | 1992 | 431 | 0.070 |
Why?
| | Clinical Medicine | 1 | 2008 | 26 | 0.070 |
Why?
| | Proteins | 1 | 2014 | 1023 | 0.070 |
Why?
| | Proto-Oncogene Proteins | 1 | 1992 | 624 | 0.070 |
Why?
| | Cell Adhesion Molecules | 2 | 2007 | 181 | 0.070 |
Why?
| | Phenotype | 4 | 2026 | 3155 | 0.070 |
Why?
| | Dogs | 3 | 2011 | 458 | 0.070 |
Why?
| | Receptors, Calcitriol | 1 | 2008 | 55 | 0.070 |
Why?
| | Microbiota | 1 | 2015 | 730 | 0.070 |
Why?
| | Catenins | 1 | 2007 | 6 | 0.070 |
Why?
| | Biomedical Research | 1 | 2014 | 717 | 0.070 |
Why?
| | Promoter Regions, Genetic | 4 | 2000 | 1246 | 0.060 |
Why?
| | Middle Aged | 12 | 2026 | 36215 | 0.060 |
Why?
| | Osteolysis | 1 | 2006 | 16 | 0.060 |
Why?
| | RNA, Messenger | 5 | 2006 | 2803 | 0.060 |
Why?
| | Molecular Sequence Data | 11 | 2000 | 2883 | 0.060 |
Why?
| | Isoflavones | 1 | 2006 | 25 | 0.060 |
Why?
| | Soybean Proteins | 1 | 2006 | 15 | 0.060 |
Why?
| | Bone Development | 1 | 2006 | 52 | 0.060 |
Why?
| | Base Sequence | 10 | 2000 | 2170 | 0.060 |
Why?
| | Cloning, Molecular | 6 | 2000 | 538 | 0.060 |
Why?
| | Transplantation, Heterologous | 3 | 2012 | 170 | 0.060 |
Why?
| | Antibodies, Monoclonal | 2 | 1993 | 1505 | 0.060 |
Why?
| | Biomarkers, Tumor | 3 | 2008 | 1321 | 0.060 |
Why?
| | Cytoskeletal Proteins | 3 | 2000 | 156 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2007 | 337 | 0.060 |
Why?
| | Chromosomes, Human, Pair 16 | 2 | 1995 | 36 | 0.050 |
Why?
| | Urinalysis | 2 | 2015 | 83 | 0.050 |
Why?
| | Gene Deletion | 2 | 1996 | 391 | 0.050 |
Why?
| | Brain Neoplasms | 2 | 2012 | 1329 | 0.050 |
Why?
| | Spectral Karyotyping | 1 | 2003 | 5 | 0.050 |
Why?
| | DNA Fingerprinting | 1 | 2003 | 28 | 0.050 |
Why?
| | Apoptosis | 1 | 2012 | 2440 | 0.050 |
Why?
| | Chromosomes, Human, Pair 9 | 2 | 2000 | 36 | 0.050 |
Why?
| | Bone Neoplasms | 3 | 2012 | 259 | 0.050 |
Why?
| | Aged, 80 and over | 6 | 2015 | 8333 | 0.050 |
Why?
| | DNA Primers | 2 | 2001 | 505 | 0.050 |
Why?
| | Keratins | 1 | 2003 | 171 | 0.050 |
Why?
| | Prostate-Specific Antigen | 1 | 2003 | 161 | 0.050 |
Why?
| | Nerve Tissue Proteins | 3 | 1993 | 591 | 0.050 |
Why?
| | Blotting, Northern | 6 | 2000 | 203 | 0.050 |
Why?
| | DNA Mutational Analysis | 2 | 2001 | 407 | 0.050 |
Why?
| | Flow Cytometry | 3 | 2015 | 1162 | 0.050 |
Why?
| | Carrier Proteins | 2 | 1996 | 728 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2015 | 3623 | 0.040 |
Why?
| | Precancerous Conditions | 1 | 2003 | 166 | 0.040 |
Why?
| | Chromosome Mapping | 4 | 1999 | 506 | 0.040 |
Why?
| | Prostatectomy | 2 | 2013 | 94 | 0.040 |
Why?
| | Aged | 9 | 2015 | 26153 | 0.040 |
Why?
| | Cytogenetics | 1 | 2001 | 11 | 0.040 |
Why?
| | Genes, Neoplasm | 1 | 2001 | 26 | 0.040 |
Why?
| | Genes, ras | 1 | 2001 | 96 | 0.040 |
Why?
| | Polymerase Chain Reaction | 5 | 2008 | 1041 | 0.040 |
Why?
| | Mice, Nude | 3 | 2011 | 679 | 0.040 |
Why?
| | Carbonic Anhydrases | 1 | 2000 | 12 | 0.040 |
Why?
| | Activated-Leukocyte Cell Adhesion Molecule | 1 | 2000 | 1 | 0.040 |
Why?
| | Neoplasm Proteins | 2 | 2000 | 441 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2003 | 523 | 0.040 |
Why?
| | Adenocarcinoma | 2 | 2012 | 925 | 0.040 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 2378 | 0.040 |
Why?
| | Pituitary Hormones | 2 | 1989 | 15 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2000 | 188 | 0.040 |
Why?
| | HeLa Cells | 1 | 2001 | 632 | 0.040 |
Why?
| | Risk | 2 | 2012 | 919 | 0.040 |
Why?
| | Proteomics | 1 | 2026 | 1188 | 0.040 |
Why?
| | Parathyroid Hormone-Related Protein | 2 | 2011 | 25 | 0.040 |
Why?
| | Cell Separation | 2 | 2011 | 305 | 0.040 |
Why?
| | Cell Communication | 1 | 2000 | 328 | 0.040 |
Why?
| | Transcription, Genetic | 3 | 2000 | 1454 | 0.030 |
Why?
| | Neoplasm Transplantation | 2 | 2011 | 246 | 0.030 |
Why?
| | RNA | 3 | 2000 | 910 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2000 | 271 | 0.030 |
Why?
| | Female | 9 | 2026 | 78845 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2026 | 2930 | 0.030 |
Why?
| | Telomerase | 1 | 2000 | 246 | 0.030 |
Why?
| | Trans-Activators | 1 | 2000 | 396 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2015 | 2953 | 0.030 |
Why?
| | Prognosis | 3 | 2015 | 4316 | 0.030 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2000 | 268 | 0.030 |
Why?
| | Restriction Mapping | 4 | 1999 | 81 | 0.030 |
Why?
| | Adult | 6 | 2026 | 40777 | 0.030 |
Why?
| | Schistosomiasis | 1 | 1996 | 50 | 0.030 |
Why?
| | alpha Catenin | 3 | 2000 | 11 | 0.030 |
Why?
| | Incidence | 2 | 2015 | 2923 | 0.030 |
Why?
| | Transfection | 3 | 2006 | 926 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2014 | 3413 | 0.030 |
Why?
| | Animals | 12 | 2012 | 38030 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2015 | 17 | 0.030 |
Why?
| | Point Mutation | 1 | 1996 | 240 | 0.030 |
Why?
| | Urine | 1 | 2015 | 64 | 0.030 |
Why?
| | DNA | 4 | 2000 | 1435 | 0.030 |
Why?
| | CD8 Antigens | 1 | 2015 | 70 | 0.030 |
Why?
| | Maryland | 1 | 2015 | 67 | 0.030 |
Why?
| | Anilides | 1 | 2015 | 84 | 0.030 |
Why?
| | Leukocyte Common Antigens | 1 | 2015 | 87 | 0.030 |
Why?
| | Chemical Precipitation | 1 | 2014 | 39 | 0.030 |
Why?
| | Disease Progression | 3 | 2015 | 2864 | 0.030 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 66 | 0.030 |
Why?
| | National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2014 | 10 | 0.030 |
Why?
| | Genes | 1 | 1995 | 227 | 0.030 |
Why?
| | CD4 Antigens | 1 | 2015 | 137 | 0.030 |
Why?
| | Reference Standards | 1 | 2014 | 177 | 0.030 |
Why?
| | Mice | 7 | 2012 | 18329 | 0.030 |
Why?
| | Amino Acid Sequence | 5 | 2000 | 2129 | 0.030 |
Why?
| | Cell Line | 4 | 1994 | 2823 | 0.030 |
Why?
| | Neoplasm Metastasis | 2 | 2011 | 688 | 0.030 |
Why?
| | Nitriles | 1 | 2015 | 207 | 0.030 |
Why?
| | PTEN Phosphohydrolase | 1 | 2015 | 165 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 310 | 0.030 |
Why?
| | Least-Squares Analysis | 1 | 2014 | 73 | 0.030 |
Why?
| | Support Vector Machine | 1 | 2014 | 33 | 0.030 |
Why?
| | Needles | 1 | 2014 | 63 | 0.020 |
Why?
| | Autopsy | 1 | 2013 | 94 | 0.020 |
Why?
| | Binding Sites | 2 | 1997 | 1310 | 0.020 |
Why?
| | Specimen Handling | 1 | 2014 | 182 | 0.020 |
Why?
| | Interdisciplinary Communication | 1 | 2014 | 200 | 0.020 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2012 | 52 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2015 | 5423 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 847 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fes | 1 | 1992 | 1 | 0.020 |
Why?
| | Equipment Design | 1 | 2014 | 525 | 0.020 |
Why?
| | Interferon-gamma | 1 | 2015 | 784 | 0.020 |
Why?
| | Antineoplastic Agents | 2 | 2015 | 2214 | 0.020 |
Why?
| | Vimentin | 1 | 1992 | 54 | 0.020 |
Why?
| | Antigens, CD | 1 | 2015 | 558 | 0.020 |
Why?
| | Exons | 3 | 1999 | 363 | 0.020 |
Why?
| | Retroviridae | 1 | 1992 | 100 | 0.020 |
Why?
| | Sequence Homology, Amino Acid | 3 | 2000 | 387 | 0.020 |
Why?
| | Calcium | 2 | 1994 | 1190 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 331 | 0.020 |
Why?
| | Neoplasms, Connective Tissue | 1 | 2011 | 3 | 0.020 |
Why?
| | Keratin-8 | 1 | 2011 | 4 | 0.020 |
Why?
| | Carcinogenicity Tests | 1 | 2011 | 13 | 0.020 |
Why?
| | Keratin-7 | 1 | 2011 | 3 | 0.020 |
Why?
| | Keratin-18 | 1 | 2011 | 12 | 0.020 |
Why?
| | Adenoviridae | 1 | 2012 | 199 | 0.020 |
Why?
| | Phenylbutyrates | 1 | 2011 | 23 | 0.020 |
Why?
| | Subcutaneous Tissue | 1 | 2011 | 26 | 0.020 |
Why?
| | Bortezomib | 1 | 2011 | 54 | 0.020 |
Why?
| | Boronic Acids | 1 | 2011 | 36 | 0.020 |
Why?
| | Spinal Cord Neoplasms | 1 | 2011 | 41 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2011 | 170 | 0.020 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 32 | 0.020 |
Why?
| | Atrophy | 1 | 2010 | 199 | 0.020 |
Why?
| | Pyrazines | 1 | 2011 | 94 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 2062 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 408 | 0.020 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2011 | 98 | 0.020 |
Why?
| | DNA, Viral | 1 | 1992 | 356 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 1992 | 848 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 637 | 0.020 |
Why?
| | Adenosine Triphosphate | 1 | 1992 | 500 | 0.020 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2010 | 178 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 1992 | 666 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 1003 | 0.020 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 1989 | 50 | 0.020 |
Why?
| | Cells, Cultured | 2 | 2012 | 4148 | 0.020 |
Why?
| | Silymarin | 1 | 2010 | 147 | 0.020 |
Why?
| | Cell Cycle | 1 | 2012 | 598 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2014 | 1997 | 0.020 |
Why?
| | Gene Expression Regulation | 2 | 1995 | 2597 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1808 | 0.020 |
Why?
| | Primaquine | 1 | 1988 | 7 | 0.020 |
Why?
| | Research Design | 1 | 2014 | 1137 | 0.020 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2010 | 317 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 1988 | 55 | 0.020 |
Why?
| | Sequence Alignment | 2 | 2000 | 362 | 0.020 |
Why?
| | Sequence Analysis, DNA | 2 | 2000 | 777 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2010 | 1266 | 0.020 |
Why?
| | Signal Transduction | 2 | 2015 | 5216 | 0.020 |
Why?
| | Risk Factors | 2 | 2014 | 10885 | 0.020 |
Why?
| | Polymorphism, Single-Stranded Conformational | 2 | 1996 | 26 | 0.020 |
Why?
| | Introns | 2 | 1999 | 255 | 0.020 |
Why?
| | Receptors, Immunologic | 1 | 1988 | 208 | 0.020 |
Why?
| | Antioxidants | 1 | 2010 | 550 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 1996 | 72 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2008 | 257 | 0.010 |
Why?
| | Luciferases | 1 | 2006 | 153 | 0.010 |
Why?
| | 3' Untranslated Regions | 1 | 2006 | 149 | 0.010 |
Why?
| | Genes, Reporter | 1 | 2006 | 277 | 0.010 |
Why?
| | Disease-Free Survival | 1 | 2007 | 767 | 0.010 |
Why?
| | Luminescent Proteins | 1 | 2006 | 186 | 0.010 |
Why?
| | Risk Assessment | 1 | 2015 | 3747 | 0.010 |
Why?
| | Mutation | 1 | 1996 | 4075 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 969 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2507 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2010 | 1356 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2007 | 1547 | 0.010 |
Why?
| | Hypoxia | 1 | 2010 | 1199 | 0.010 |
Why?
| | Androgens | 1 | 2003 | 181 | 0.010 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 2121 | 0.010 |
Why?
| | RNA, Neoplasm | 2 | 1992 | 83 | 0.010 |
Why?
| | Prospective Studies | 1 | 2014 | 8057 | 0.010 |
Why?
| | Gene Library | 2 | 1992 | 122 | 0.010 |
Why?
| | DNA Footprinting | 1 | 2000 | 33 | 0.010 |
Why?
| | Fibroblast Growth Factor 8 | 1 | 2000 | 27 | 0.010 |
Why?
| | Lentivirus | 1 | 2000 | 61 | 0.010 |
Why?
| | Plasmids | 2 | 1992 | 373 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2000 | 156 | 0.010 |
Why?
| | Scintillation Counting | 1 | 2000 | 4 | 0.010 |
Why?
| | Electrophoresis, Agar Gel | 1 | 2000 | 25 | 0.010 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2000 | 45 | 0.010 |
Why?
| | Carbonic Anhydrase IX | 1 | 2000 | 4 | 0.010 |
Why?
| | Transduction, Genetic | 1 | 2000 | 132 | 0.010 |
Why?
| | Stromal Cells | 1 | 2000 | 121 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2000 | 85 | 0.010 |
Why?
| | Nucleic Acid Hybridization | 2 | 1992 | 187 | 0.010 |
Why?
| | Desmoplakins | 1 | 2000 | 24 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2000 | 247 | 0.010 |
Why?
| | Aging | 1 | 2010 | 1969 | 0.010 |
Why?
| | Prostatic Intraepithelial Neoplasia | 1 | 1999 | 9 | 0.010 |
Why?
| | Isoenzymes | 1 | 2000 | 294 | 0.010 |
Why?
| | Bacterial Proteins | 1 | 2006 | 967 | 0.010 |
Why?
| | Neuroendocrine Secretory Protein 7B2 | 2 | 1989 | 2 | 0.010 |
Why?
| | Rats | 3 | 1993 | 5584 | 0.010 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2000 | 224 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 1999 | 52 | 0.010 |
Why?
| | Organ Specificity | 1 | 2000 | 309 | 0.010 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2000 | 177 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2000 | 335 | 0.010 |
Why?
| | Protein Isoforms | 1 | 2000 | 397 | 0.010 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2000 | 153 | 0.010 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2000 | 592 | 0.010 |
Why?
| | Diet | 1 | 2006 | 1277 | 0.010 |
Why?
| | Helix-Loop-Helix Motifs | 1 | 1997 | 12 | 0.010 |
Why?
| | Reference Values | 1 | 1999 | 798 | 0.010 |
Why?
| | Sp1 Transcription Factor | 1 | 1997 | 24 | 0.010 |
Why?
| | Base Composition | 1 | 1997 | 82 | 0.010 |
Why?
| | Dinucleoside Phosphates | 1 | 1997 | 31 | 0.010 |
Why?
| | beta Catenin | 1 | 2000 | 254 | 0.010 |
Why?
| | Cell Survival | 1 | 2000 | 1100 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1997 | 190 | 0.010 |
Why?
| | Tissue Distribution | 1 | 1997 | 335 | 0.010 |
Why?
| | Egypt | 1 | 1996 | 13 | 0.010 |
Why?
| | Netherlands | 1 | 1996 | 84 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 2000 | 1368 | 0.010 |
Why?
| | United States | 1 | 2014 | 16098 | 0.010 |
Why?
| | Lung Neoplasms | 1 | 1989 | 2664 | 0.010 |
Why?
| | Single-Strand Specific DNA and RNA Endonucleases | 1 | 1994 | 10 | 0.010 |
Why?
| | TATA Box | 1 | 1994 | 20 | 0.010 |
Why?
| | DNA Probes | 1 | 1994 | 59 | 0.010 |
Why?
| | Sequence Homology | 1 | 1994 | 43 | 0.010 |
Why?
| | Chickens | 1 | 1994 | 179 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1994 | 272 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 1995 | 191 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1995 | 506 | 0.010 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 1993 | 157 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2000 | 1480 | 0.010 |
Why?
| | Epitopes | 1 | 1993 | 473 | 0.010 |
Why?
| | Alternative Splicing | 1 | 1993 | 247 | 0.010 |
Why?
| | Kidney | 1 | 1998 | 1497 | 0.010 |
Why?
| | Biological Evolution | 1 | 1994 | 467 | 0.000 |
Why?
| | Protein Biosynthesis | 1 | 1993 | 452 | 0.000 |
Why?
| | Transcription Factors | 1 | 1997 | 1734 | 0.000 |
Why?
| | Carcinoma, Small Cell | 1 | 1989 | 172 | 0.000 |
Why?
| | Asialoglycoprotein Receptor | 1 | 1988 | 6 | 0.000 |
Why?
| | Protein Conformation | 1 | 1988 | 938 | 0.000 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1988 | 372 | 0.000 |
Why?
| | Liver Neoplasms | 1 | 1988 | 776 | 0.000 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1989 | 1189 | 0.000 |
Why?
| | Adolescent | 1 | 1998 | 22530 | 0.000 |
Why?
|
|
Van Bokhoven's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|